Neuropsychological functioning and quality of life during the first year after completing chemotherapy for breast cancer

Psycho-Oncology

Volumn 19, Issue 5, 2010, Pages 535-544

  Reid Arndt, Stephanie A ^a   Hsieh, Catherine ^a   Perry, Michael C ^b  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

Author keywords

Cancer; Chemotherapy; Cognitive function; Neuropsychological tests; Oncology; Quality of life

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COGNITION; DEPRESSION; EMOTIONALITY; FATIGUE; FEMALE; HUMAN; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SOCIAL SUPPORT;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COGNITION DISORDERS; FEMALE; HUMANS; NEUROPSYCHOLOGICAL TESTS; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 77951098847     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.1581     Document Type: Article

References (49)

1. Ahles TA, Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest 2001;19:812-820. (Pubitemid 33151212)
2. Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2003;22(11): 2233-2239.
3. Reid-Arndt SA. The potential for neuropsychology to inform functional outcomes research with breast cancer survivors. NeuroRehabilitation 2006;21(1):51-64. (Pubitemid 43748207)
4. Schagen SB, van Dam FSAM, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-650. (Pubitemid 29075285)
5. Brezden CB, Phillips K, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695-2701. (Pubitemid 30463551)
6. Ahles TA, Saykin A, Furstenberg CT et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002;20:485-493. (Pubitemid 34072533)
7. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz B, Belin TR. Quality of life in long-term, disease-free survivors of breast cancer: a follow-up study. J Natl Cancer Inst 2002;94:39-49. (Pubitemid 34082842)
8. Jansen CE, Miaskowski C, Dodd M, Dowling G, Kramer J. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 2005;104(10):2222-2233. (Pubitemid 41579970)
9. Van Dam FSAM, Schagen SB, Muller MJ et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high dose versus standard-dose chemotherapy. J Natl Cancer Inst 1998;90:210-218.
10. Van Oosterhout AGM, Ganzevles PGJ, Wilmink JT, de Geus BWJ, van Vonderen RGMW, Wijnstra A. Sequelae in long-term survivors of small cell lung cancer. Int J Radiat Oncol 1996;34:1037-1044. (Pubitemid 26105441)
11. Wieneke MH, Dienst ER. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology 1995;41: 61-66. (Pubitemid 26093776)
12. Meyers CA, Byrne KS, Komaki R. Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer 1995;12:231-235.
13. Stewart A, Bielajew C, Collins B, Parkinson M, Tomiak E. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006;20: 76-89.
14. Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips K. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn 2005;59:60-70. (Pubitemid 41405841)
15. Anderson-Hanley C, Sherman ML, Riggs R, Agocha VB, Compas BE. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc 2003;9(7):967-982. (Pubitemid 37428441)
16. Vardy J, Wefel JS, Ahles T, Tannock IF, Schagen SB. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol 2008;19:623-629. (Pubitemid 351461030)
17. Saykin AJ, Ahles TA, McDonald BC. Mechanisms of chemotherapy-induced cognitive disorders: neuropsychological, pathophysiological, and neuroimaging perspectives. Semin Clin Neuropsychiatry 2003;8(4): 201-216.
18. Inagaki M, Yoshikawa E, Matsuoka Y et al. Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 2007;109:146-156. (Pubitemid 46120202)
19. Silverman DH, Dy CJ, Castellon SA et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 2007;103:303-311.
20. Saykin AJ. Altered brain activation following systemic chemotherapy for breast cancer: interim analysis from a prospective study. J Int Neuropsychol Soc 2006;12:131.
21. Mehlsen M, Pedersen AD, Jensen AB, Zachariae R. No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psycho-Oncology 2009;18(3):248-257.
22. Jenkins V, Shilling V, Deutsch G et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 2006;94:828-834.
23. Bender CM, Sereika SM, Berga SL et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology 2005;15:422-430.
24. Wefel JS, Lenzi R, Theriault R et al. 'Chemobrain' in breast carcinoma?: a prologue. Cancer 2004;101: 466-475.
25. Lauver DR, Connolly-Nelson K, Vang P. Stressors and coping strategies among female cancer survivors after treatments. Cancer Nurs 2007;30(2):101-111. (Pubitemid 46573047)
26. Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psycho-Oncology 2006; 15(10):921-930. (Pubitemid 44612891)
27. Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR. Cancer-related fatigue: the scale of the problem. Oncologist 2007;12(Suppl 1):4-10.
28. Beijer S, Kempen GI, Pijls-Johannesma MC, de Graeff A, Dagnelie PC. Determinants of overall quality of life in preterminal cancer patients. Int J Cancer 2008:123(1): 232-235. (Pubitemid 351705214)
29. Bower JE. Cancer-related fatigue: links with inflammation in cancer patients and survivors. Brain Behav Immun 2007;21(7):863-871.
30. Stanton AL, Revenson TA, Tennen H. Health psychology: psychological adjustment to chronic disease. Annu Rev Psychol 2007;58:565-592.
31. Lezak MD, Howieson DB, Loring DW. Neuropsychological Assessment (4th edn). Oxford University Press: New York, 2004.
32. Wechsler D. WMS-III Administration and Scoring Manual. The Psychological Corporation: San Antonio, TX, 1997.
33. Taylor EM. Psychological Appraisal of Children with Cerebral Deficits. Harvard University Press: Cambridge, MA, 1959.
34. Reitan RM. The relation of the trail making test to organic brain damage. J Consult Psychol 1955; 16:383-394.
35. Golden CJ. Stroop Color and Word Test. Stoelting: Chicago, IL, 1978.
36. Benton AL, Hamsher KdeS. Multilingual Aphasia Examination. AJA Associates: Iowa City, IA, 1989.
37. Strauss E, Sherman EMS, Spreen O. A Compendium of Neuropsychological Tests: Administration, Norms, and Commentary (3rd edn). Oxford University Press: New York, 2006.
38. Baker F, Denniston M, Zabora J, Polland A, Dudley WN. A POMS short form for cancer patients: psychometric and structural evaluation. Psycho-Oncology 2002;11(4): 273-281. (Pubitemid 34987586)
39. Farmer JE, Clark MJ, Sherman AK. Rural versus urban social support seeking as a moderating variable in traumatic brain injury outcome. J Head Trauma Rehabil 2003;18(2):116-127.
40. Beck AT, Steer RA, Brown GK. Beck Depression Inventory (2nd edn). The Psychological Corporation: San Antonio, 1996.
41. Bettencourt BA, Sheldon K. Social roles as mechanism for psychological need satisfaction within social groups. J Pers Soc Psychol 2001;81(6):1131-1143. (Pubitemid 33596194)
42. Sheldon K, Bettencourt BA. Psychological need-satisfaction and subjective well-being within social groups. Br J Soc Psychol 2002;41:25-38.
43. Bernhard J, Sullivan M, Hurny C, Coates AS, Rudenstam CM. Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 2001;84(9):1156-1165. (Pubitemid 32511331)
44. Brady MJ, Cella DF, Mo F et al. Reliability and validity of the functional assessment of cancer therapy - breast quality of life instrument. J Clin Oncol 1997;15(3): 974-986. (Pubitemid 27106280)
45. Reid-Arndt SA, Yee A, Perry MC, Hsieh C. Cognitive and psychological factors associated with early post-treatment functional outcomes in breast cancer survivors. J Psychosocial Oncol; accepted.
46. Vardy J, Rourke S, Tannock IF. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol 2007;25(17):2455-2463. (Pubitemid 46999217)
47. Jacobson NS, Traux P. Clinical significance: a statistical approach to defining the meaningful change in psychotherapy research. J Consult Clin Psychol 1991;59(1): 12-19.
48. Lineweaver TT, Chelune GJ. Use of the WAIS-III and WMS-III in the context of serial assessments: interpreting reliable and meaningful change. In Clinical Interpretation of the WAIS-III and WMS-III, Tulsky DS, Saklofske DH, Chelune GJ, Heaton RK, Ivnik RJ, Bornstein R, Prifitera A, Ledbetter MF (eds). Elsevier Science: San Diego, CA, 2003.
49. Ganz PA, Guadagnoli E, Landrum MB, Lash TL, Rakowski W, Silliman RA. Breast cancer in older women: quality of life and psychosocial adjustment in the 15 months after diagnosis. J Clin Oncol 2003;21(21):4027-4033. (Pubitemid 46606218)